Skip to main content

Table 5 Hematologic and non-hematologic toxicity (NCI-CTC version 3.0)

From: Phase II study of weekly paclitaxel and capecitabine in patients with metastatic or recurrent esophageal squamous cell carcinoma

Toxicity NCI-CTC Grade (n = 32)
   0 1 2 3 4
   No. (%) No. (%) No. (%) No. (%) No. (%)
Hematologic
  Leukocytopenia 4 (12.5) 9 (28.1) 11 (34.4) 8 (25.0) 0 (0.0)
  Neutropenia 5 (15.6) 3 (9.4) 7 (21.9) 10 (31.3) 7 (21.9)
  Anemia 1 (3.1) 12 (37.5) 17 (53.1) 2 (6.3) 0 (0.0)
  Thrombocytopenia 28 (87.5) 4 (12.5) 0 (0.0) 0 (0.0) 0 (0.0)
Non-hematologic
Neurology Neuropathy 18 (56.3) 8 (25.0) 5 (15.6) 1 (3.1) 0 (0.0)
GI Stomatitis 13 (40.6) 12 (37.5) 4 (12.5) 3 (9.4) 0 (0.0)
  Anorexia 10 (31.3) 17 (53.1) 5 (15.6) 0 (0.0) 0 (0.0)
  Nausea/Vomiting 16 (50.0) 16 (50.0) 0 (0.0) 0 (0.0) 0 (0.0)
  Constipation 23 (71.9) 6 (18.8) 3 (9.4) 0 (0.0) 0 (0.0)
  Diarrhea 24 (75.0) 7 (21.9) 1 (3.1) 0 (0.0 0 (0.0)
Hepatic AST↑ 27 (84.4) 4 (12.5) 1 (3.1) 0 (0.0) 0 (0.0)
  ALT↑ 29 (90.6) 3 (9.4) 0 (0.0) 0 (0.0) 0 (0.0)
  Bilirubin↑ 25 (78.1) 6 (18.8) 1 (3.1) 0 (0.0) 0 (0.0)
Renal Creatinine↑ 23 (71.9) 8 (25.0) 1 (3.1) 0 (0.0) 0 (0.0)
Dermatology Alopecia 5 (15.6) 16 (50.0) 11 (34.4) 0 (0.0) 0 (0.0)
  Rash 25 (78.1) 5 (15.6) 2 (6.3) 0 (0.0) 0 (0.0)
  Itching 27 (84.4) 5 (15.6) 0 (0.0) 0 (0.0) 0 (0.0)
  Hyperpigmentation 20 (62.5) 10 (31.3) 2 (6.3) 0 (0.0) 0 (0.0)
  Nail change 24 (75.0) 3 (9.4) 4 (12.5) 1 (3.1) 0 (0.0)
  Hand-foot syndrome 18 (56.3) 9 (28.1) 4 (12.5) 1 (3.1) 0 (0.0)
Others Asthenia 8 (25.0) 16 (50.0) 6 (18.8) 2 (6.3) 0 (0.0)
  Myalgia 23 (71.9) 8 (25.0) 1 (3.1) 0 (0.0) 0 (0.0)
  Febrile neutropenia 30 (93.8) 0 (0.0) 0 (0.0) 2 (6.3) 0 (0.0)
  Pneumonitis 30 (93.8) 1 (3.1) 0 (0.0) 1 (3.1) 0 (0.0)